对肾癌生物学、评估及治疗的认识在25年中的演变与进展
A 25 year perspective on the evolution and advances in an understanding of the biology, evaluation and treatment of kidney cancer.
作者信息
Geynisman Daniel M, Maranchie Jodi K, Ball Mark W, Bratslavsky Gennady, Singer Eric A
机构信息
Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA.
Department of Urology, University of Pittsburgh, Pittsburgh, PA.
出版信息
Urol Oncol. 2021 Sep;39(9):548-560. doi: 10.1016/j.urolonc.2021.04.038. Epub 2021 Jun 4.
Abstract
The diagnosis, evaluation and management of patients with renal cell carcinoma has transformed in the 21st century. Utilizing biological discoveries and technological advances, the field has moved from blunt surgical and largely ineffective medical treatments, to nuanced and fine-tuned approaches based on biology, extent of disease and patient preferences. In this review we will summarize the last 25 years of progress in kidney cancer.
摘要
21世纪以来，肾细胞癌患者的诊断、评估及治疗方式发生了转变。借助生物学领域的发现和技术进步，该领域已从简单粗暴的手术治疗以及效果不佳的药物治疗，转变为基于生物学特性、疾病范围和患者偏好的细致入微且经过精准调整的治疗方法。在这篇综述中，我们将总结过去25年里肾癌研究取得的进展。
相似文献
1
A 25 year perspective on the evolution and advances in an understanding of the biology, evaluation and treatment of kidney cancer.
Urol Oncol. 2021 Sep;39(9):548-560. doi: 10.1016/j.urolonc.2021.04.038. Epub 2021 Jun 4.
2
A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of urothelial cancer.
Urol Oncol. 2021 Sep;39(9):528-547. doi: 10.1016/j.urolonc.2021.05.036. Epub 2021 Jul 29.
3
A 25-year perspective on evaluation and understanding of biomarkers in urologic cancers.
Urol Oncol. 2021 Sep;39(9):602-617. doi: 10.1016/j.urolonc.2021.06.010. Epub 2021 Jul 24.
4
[EAU guidelines for prostate cancer: to screen or not to screen?].
Actas Urol Esp. 2012 Jan;36(1):1. doi: 10.1016/j.acuro.2011.07.017. Epub 2011 Oct 19.
5
Transitional cell carcinoma of the pelvicalices and ureter.
AJR Am J Roentgenol. 1990 Oct;155(4):713-22. doi: 10.2214/ajr.155.4.2119098.
6
Drugs and risk of cancer.
Scand J Urol. 2017 Jun;51(3):212-218. doi: 10.1080/21681805.2017.1329905.
7
Contemporary Evaluation and Management of Upper Tract Urothelial Cancer.
Urology. 2016 Aug;94:17-23. doi: 10.1016/j.urology.2015.12.035. Epub 2016 Feb 2.
8
[Renal cell carcinoma].
Urologe A. 2006 Sep;45 Suppl 4:74-84. doi: 10.1007/s00120-006-1136-1.
9
Urothelial carcinoma of the bladder and the upper tract: disparate twins.
J Urol. 2013 Apr;189(4):1214-21. doi: 10.1016/j.juro.2012.05.079. Epub 2012 Sep 27.
10
[A case of synchronous ipsilateral renal cell carcinoma and ureteral transitional cell carcinoma].
Hinyokika Kiyo. 2000 Feb;46(2):113-6.
引用本文的文献
1
Association of Histologic Growth Patterns and Some Histopathologic Features in Clear Cell Renal Cell Carcinoma with Patient's Survival after Nephrectomy: A Cross-Sectional Study.
Iran J Pathol. 2025 Spring;20(2):198-206. doi: 10.30699/ijp.2025.2033228.3319. Epub 2025 Mar 10.
2
Adjuvant therapy in renal cell carcinoma (RCC): progress, at last.
Transl Cancer Res. 2024 Nov 30;13(11):6448-6462. doi: 10.21037/tcr-23-2247. Epub 2024 Aug 12.
3
The Novel HDAC Inhibitor OBP-801 Promotes MHC Class I Presentation Through LMP2 Upregulation, Enhancing the PD-1-Targeting Therapy in Clear Cell Renal Cell Carcinoma.
Cancers (Basel). 2024 Dec 4;16(23):4058. doi: 10.3390/cancers16234058.
4
Patients with metastatic renal cell carcinoma who receive immune-targeted therapy may derive survival benefit from nephrectomy.
BMC Cancer. 2023 Oct 6;23(1):943. doi: 10.1186/s12885-023-11408-x.
5
Preclinical optimization of a diode laser-based clamp-free partial nephrectomy in a large animal model.
Sci Rep. 2023 Jun 7;13(1):9237. doi: 10.1038/s41598-023-35891-1.
6
Determining Front-Line Therapeutic Strategy for Metastatic Clear Cell Renal Cell Carcinoma.
Cancers (Basel). 2022 Sep 22;14(19):4607. doi: 10.3390/cancers14194607.
7
Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma.
Oncologist. 2023 Feb 8;28(2):157-164. doi: 10.1093/oncolo/oyac195.
8
Renal Cell Carcinoma with Cardiac Metastases: A Case Report and Review of the Literature.
J Kidney Cancer VHL. 2022 May 25;9(2):32-38. doi: 10.15586/jkcvhl.v9i2.229. eCollection 2022.
9
New Paradigms for Cytoreductive Nephrectomy.
Cancers (Basel). 2022 May 27;14(11):2660. doi: 10.3390/cancers14112660.
10
Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with -deficiency allows for selective targeting of clear cell renal cell carcinoma.
Cell Cycle. 2022 May;21(10):1103-1119. doi: 10.1080/15384101.2022.2041783. Epub 2022 Mar 4.
本文引用的文献
1
Precision Surgery and Kidney Cancer: Knowledge of Genetic Alterations Influences Surgical Management.
Genes (Basel). 2021 Feb 11;12(2):261. doi: 10.3390/genes12020261.
2
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13.
3
Cytoreductive nephrectomy for metastatic renal cell carcinoma, the ultimate urologic 'Choosing Wisely' campaign: a narrative review.
Transl Cancer Res. 2020 Nov;9(11):7337-7349. doi: 10.21037/tcr-20-2343.
4
Clinical and Molecular Characterization of Microphthalmia-associated Transcription Factor (MITF)-related Renal Cell Carcinoma.
Urology. 2021 Mar;149:89-97. doi: 10.1016/j.urology.2020.11.025. Epub 2020 Nov 24.
5
Sarcomatoid renal cell carcinoma: biology, natural history and management.
Nat Rev Urol. 2020 Dec;17(12):659-678. doi: 10.1038/s41585-020-00382-9. Epub 2020 Oct 13.
6
Combination drug regimens for metastatic clear cell renal cell carcinoma.
World J Clin Oncol. 2020 Aug 24;11(8):541-562. doi: 10.5306/wjco.v11.i8.541.
7
Small Renal Mass Surveillance: Histology-specific Growth Rates in a Biopsy-characterized Cohort.
Eur Urol. 2020 Sep;78(3):460-467. doi: 10.1016/j.eururo.2020.06.053. Epub 2020 Jul 14.
8
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.
Cancer. 2020 Sep 15;126(18):4156-4167. doi: 10.1002/cncr.33033. Epub 2020 Jul 16.
9
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial.
J Immunother Cancer. 2020 Jul;8(2). doi: 10.1136/jitc-2020-000891.
10
Single-port robotic-assisted partial nephrectomy: initial clinical experience and lessons learned for successful outcomes.
J Robot Surg. 2021 Apr;15(2):293-298. doi: 10.1007/s11701-020-01106-2. Epub 2020 Jun 20.
Zotero 插件